140 related articles for article (PubMed ID: 30156102)
1. Asbestos: Modern Insights for Toxicology in the Era of Engineered Nanomaterials.
Felley-Bosco E; MacFarlane M
Chem Res Toxicol; 2018 Oct; 31(10):994-1008. PubMed ID: 30156102
[TBL] [Abstract][Full Text] [Related]
2. Consensus Report of the 2015 Weinman International Conference on Mesothelioma.
Carbone M; Kanodia S; Chao A; Miller A; Wali A; Weissman D; Adjei A; Baumann F; Boffetta P; Buck B; de Perrot M; Dogan AU; Gavett S; Gualtieri A; Hassan R; Hesdorffer M; Hirsch FR; Larson D; Mao W; Masten S; Pass HI; Peto J; Pira E; Steele I; Tsao A; Woodard GA; Yang H; Malik S
J Thorac Oncol; 2016 Aug; 11(8):1246-1262. PubMed ID: 27453164
[TBL] [Abstract][Full Text] [Related]
3. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
[TBL] [Abstract][Full Text] [Related]
5. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
6. Mesothelioma and Colorectal Cancer: Report of Four Cases with Synchronous and Metachronous Presentation.
Serio G; Pezzuto F; Fortarezza F; Marzullo A; Delfino MC; d'Amati A; Romano DE; Maniglio S; Caporusso C; Lettini T; Cavone D; Vimercati L
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269773
[TBL] [Abstract][Full Text] [Related]
7. Malignant Mesothelioma and Its Non-Asbestos Causes.
Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
[TBL] [Abstract][Full Text] [Related]
8. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma.
Carbone M; Minaai M; Takinishi Y; Pagano I; Yang H
J Transl Med; 2023 Oct; 21(1):749. PubMed ID: 37880686
[TBL] [Abstract][Full Text] [Related]
9. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
10. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.
Napolitano A; Pellegrini L; Dey A; Larson D; Tanji M; Flores EG; Kendrick B; Lapid D; Powers A; Kanodia S; Pastorino S; Pass HI; Dixit V; Yang H; Carbone M
Oncogene; 2016 Apr; 35(15):1996-2002. PubMed ID: 26119930
[TBL] [Abstract][Full Text] [Related]
11. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.
Andujar P; Wang J; Descatha A; Galateau-Sallé F; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Renier A; Zucman-Rossi J; Pairon JC; Jaurand MC
Lung Cancer; 2010 Jan; 67(1):23-30. PubMed ID: 19375815
[TBL] [Abstract][Full Text] [Related]
12. Air pollution and asbestos carcinogenesis: investigation of possible synergism.
Selikoff IJ
IARC Sci Publ (1971); 1977; (16):247-53. PubMed ID: 873540
[No Abstract] [Full Text] [Related]
13. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
[TBL] [Abstract][Full Text] [Related]
14. Why some, but not all, countries have banned asbestos.
Bahk J; Choi Y; Lim S; Paek D
Int J Occup Environ Health; 2013; 19(2):127-35. PubMed ID: 23684271
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal mesothelioma: the site of origin matters.
Kindler HL
Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
[TBL] [Abstract][Full Text] [Related]
16. A comparison of asbestos fiber potency and elongate mineral particle (EMP) potency for mesothelioma in humans.
Garabrant DH; Pastula ST
Toxicol Appl Pharmacol; 2018 Dec; 361():127-136. PubMed ID: 30077661
[TBL] [Abstract][Full Text] [Related]
17. Puzzling Results from
Rizzardi C; Athanasakis E; Cammisuli F; Monego SD; DE Spelorzi YCC; Costantinides F; Giudici F; Pinamonti M; Canzonieri V; Melato M; Pascolo L
Anticancer Res; 2017 Jun; 37(6):3073-3083. PubMed ID: 28551647
[TBL] [Abstract][Full Text] [Related]
18. Asbestos exposure and mesothelioma incidence and mortality in Bulgaria.
Vangelova K; Dimitrova I
Rev Environ Health; 2016 Jun; 31(2):203-9. PubMed ID: 27180335
[TBL] [Abstract][Full Text] [Related]
19. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis of malignant mesothelioma.
Sekido Y
Carcinogenesis; 2013 Jul; 34(7):1413-9. PubMed ID: 23677068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
